Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) Net Margin: 2020-2025

Historic Net Margin for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Sep 2025 value amounting to -108.23%.

  • Maravai Lifesciences Holdings' Net Margin rose 14161.00% to -108.23% in Q3 2025 from the same period last year, while for Sep 2025 it was -111.11%, marking a year-over-year increase of 579.00%. This contributed to the annual value of -100.17% for FY2024, which is 5228.00% down from last year.
  • Maravai Lifesciences Holdings' Net Margin amounted to -108.23% in Q3 2025, which was up 26.55% from -147.34% recorded in Q2 2025.
  • In the past 5 years, Maravai Lifesciences Holdings' Net Margin ranged from a high of 64.57% in Q2 2022 and a low of -249.84% during Q3 2024.
  • Its 3-year average for Net Margin is -86.50%, with a median of -81.45% in 2024.
  • Its Net Margin has fluctuated over the past 5 years, first slumped by 22,726bps in 2024, then surged by 14,161bps in 2025.
  • Over the past 5 years, Maravai Lifesciences Holdings' Net Margin (Quarterly) stood at 55.64% in 2021, then slumped by 1,293bps to 42.71% in 2022, then plummeted by 19,105bps to -148.34% in 2023, then spiked by 6,689bps to -81.45% in 2024, then spiked by 14,161bps to -108.23% in 2025.
  • Its Net Margin was -108.23% in Q3 2025, compared to -147.34% in Q2 2025 and -112.81% in Q1 2025.